Treatment strategies for hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation

Korean Journal of Hematology

Volumn 47, Issue 1, 2012, Pages 8-16

  Currin, Erin Siobhain R ^a   Gopal, Ajay K ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allogeneic transplant; Antibody drug conjugates; Hdac inhibitor; Hodgkin lymphoma; Imid, mTOR

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; GEMCITABINE; LENALIDOMIDE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAVELBINE; PANOBINOSTAT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; VINBLASTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER PATIENT; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG MYCOSIS; LUNG TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PYELONEPHRITIS; RADIATION DOSE; REVIEW; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

EID: 84866895484     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2012.47.1.8     Document Type: Review

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14:1421-30.
4. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:653-62.
5. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71.
6. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-23.
7. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000;18:2615-9.
8. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.Ann Oncol 2007;18:1071-9.
9. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762-7.
10. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523-9.
11. Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 2009;31:2290-311.
12. De Filippi R, Aldinucci D, Galati D, et al. Effect of bendamustine on apoptosis and colony-initiating precursors in Hodgkin lymphoma cells. J Clin Oncol 2011;29(Suppl):abst e18559.
13. Moskowitz AJ, Hamlin PA, Gerecitano J, et al. Bendamustine is highly active in heavily pre-treated relapsed and refractoryhodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood 2009;114:abst 720.
14. Shao W, Growney J, Feng Y, et al. Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. AACR 2008:abst 735.
15. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 2009;147:97-101.
16. Sureda A, Younes A, Ben-Yehuda D, et al. Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Blood 2010;116:abst 419.
17. Kuruvilla J, Taylor D, Wang L, Blattler C, Keating A, Crump M. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2008;112:abst 3052.
18. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25.
19. Boll B, Fuchs M, Reiners KS, Engert A, Borchmann P. Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116:abst 2828.
20. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
21. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-4.
22. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002;20:1278-87.
23. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-4.
24. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep 2010;5:135-9.
25. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003;21:3526-34.
26. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36.
27. Bartlett NL, Younes A, Carabasi MH, et al. Phase I study of SGN-30,a chimeric monoclonal antibody (mAb) in patients with refractory or recurrent CD30+ hematologic malignancies. Blood2002;100:362a-3a(abst 1403).
28. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111: 1848-54.
29. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9.
30. Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011;29(Suppl):abst 8031.
31. Younes A, Barlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21.
32. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
33. Forero-Torres A, Berryman RB, Advani RH, et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). Blood 2011;118:abst 3711.
34. Younes A, Connors JM, Park SI, Hunder NN, Ansell SM. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Blood 2011;118:abst 955.
35. Chen RW, Forman SJ, Palmer J, et al. Brentuximab vedotin (SGN- 35) enables successful reduced intensity allogeneic hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma. Blood 2011;118:abst 664.
36. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1279-87.
37. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 21997;20:859-63.
38. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000;6:272-9.
39. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455-62.
40. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005;35:943-51.
41. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257-64.
42. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009;94:230-8.
43. Ram R, Gooley TA, Maloney DG, et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:1537-45.
44. Gopal AK, Ramchandren R, Berryman RB, et al. Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series. EBMT 2011:abst 0267.